Clinical-Stage Biotech Committed to Advancing Novel Therapies for Rare Endocrine Disorders
Spruce Biosciences is a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders. Our team has extensive expertise in endocrinology and orphan drug development and our lead product candidate, Tildacerfont (SPR001), has the potential to be the first FDA-approved therapy for congenital adrenal hyperplasia (CAH), a rare endocrine disease. We are headquartered in San Francisco and have raised a total of $28M.
Or lead program, SPR001, is currently in Phase 2 clinical trials for CAH. For more information on CAH please visit our patient resources section. If you are a patient interested in learning more about our clinical trials and may be eligible to participate, please visit our clinical trials page.